BS_7Z93ZYMS
pilocytic astrocytoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- pilocytic astrocytoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- pilocytic astrocytoma
- age_years
- 2.592
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.645
- INTERFERON_GAMMA_RESPONSE+0.574
- CHOLESTEROL_HOMEOSTASIS+0.536
- ALLOGRAFT_REJECTION+0.497
- IL6_JAK_STAT3_SIGNALING+0.447
- PROTEIN_SECRETION+0.407
- ANDROGEN_RESPONSE+0.378
- COMPLEMENT+0.335
- MYOGENESIS+0.330
- INFLAMMATORY_RESPONSE+0.325
Top 10 suppressed
- E2F_TARGETS-0.517
- G2M_CHECKPOINT-0.478
- MYC_TARGETS_V2-0.453
- MYC_TARGETS_V1-0.369
- DNA_REPAIR-0.289
- WNT_BETA_CATENIN_SIGNALING-0.270
- SPERMATOGENESIS-0.218
- UV_RESPONSE_UP-0.178
- MITOTIC_SPINDLE-0.173
- UNFOLDED_PROTEIN_RESPONSE-0.095
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_MY9D8XZ1 | pilocytic astrocytoma | — | 0.933 |
| 2 | BS_X16PENSA | pilocytic astrocytoma | — | 0.921 |
| 3 | BS_V89HGTET | pilocytic astrocytoma | — | 0.918 |
| 4 | BS_V3REENH9 | pilocytic astrocytoma | — | 0.912 |
| 5 | BS_NRPG5K4K | low-grade glioma | — | 0.912 |
| 6 | BS_MF9X3PKH | low-grade glioma | — | 0.904 |
| 7 | BS_3W07B2TG | subependymal giant cell astrocytoma(SEGA) | — | 0.902 |
| 8 | BS_014EVM2D | low-grade glioma | — | 0.901 |
| 9 | BS_Z7Y2466H | pilocytic astrocytoma | — | 0.897 |
| 10 | BS_F8N6CFQE | low-grade glioma | — | 0.897 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.645 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.574 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.536 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.497 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.447 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.407 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.378 | Inavolisib | — uncovered |
| COMPLEMENT | 0.335 | Inavolisib | — uncovered |
| MYOGENESIS | 0.330 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.325 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.315 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.283 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.264 | Inavolisib | — uncovered |
| APOPTOSIS | 0.231 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.226 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.224 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.216 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.209 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.193 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.182 | Inavolisib | — uncovered |